Prof. Dr. med. Peter Hammerer - Urologie, Braunschweig - Publikationen

1: Yassin DJ, Yassin AA, Hammerer PG. Combined testosterone and vardenafil
treatment for restoring erectile function in hypogonadal patients who failed to
respond to testosterone therapy alone. J Sex Med. 2014 Feb;11(2):543-52.

2: Yassin DJ, El Douaihy Y, Yassin AA, Kashanian J, Shabsigh R, Hammerer PG.
Lower urinary tract symptoms improve with testosterone replacement therapy in men
with late-onset hypogonadism: 5-year prospective, observational and longitudinal
registry study. World J Urol. 2013 Oct 18.

3: Miller K, Hammerer P, Eichenauer R, Geiges G, Lehmann J, Rodemer G, Ruessel C,
Rulf W, Suttmann H, Wolff JM. [Value of intermittent androgen deprivation in the
context of the current data situation]. Aktuelle Urol. 2013 Jul;44(4):271-6.

4: Hammerer P, Madersbacher S. Reply: Landmarks in hormonal therapy for prostate
cancer. BJU Int. 2013 Mar;111(3):E13-5.

5: Słojewski M, Safranow K, Jakubowska K, Olszewska M, Pawlik A, Juzyszyn Z,
Droździk M, Chlubek D, Hammerer P, Sikorski A. Can we predict urinary stone
composition based on an analysis of microelement concentration in the hair and
urine? Adv Clin Exp Med. 2012 Jul-Aug;21(4):469-75.

6: Hammerer P, Madersbacher S. Landmarks in hormonal therapy for prostate cancer.
BJU Int. 2012 Oct;110 Suppl 1:23-9.

7: Braunwarth H, Brill FH, Hegeholz D, Hammerer P. [The influence of viscosity of
synthetic urine on the flow rate through catheters]. Urologe A. 2012

8: Madersbacher S, Alcaraz A, Emberton M, Hammerer P, Ponholzer A, Schröder FH,
Tubaro A. The influence of family history on prostate cancer risk: implications
for clinical management. BJU Int. 2011 Mar;107(5):716-21.

9: Börgermann C, Loertzer H, Hammerer P, Fornara P, Graefen M, Rübben H.
[Problems, objective, and substance of early detection of prostate cancer].
Urologe A. 2010 Feb;49(2):181-9.

10: Zugor V, Labanaris AP, Rezaei-Jafari MR, Hammerer P, Dembowski J, Witt J,
Wucherpfennig W. TVT vs. TOT: a comparison in terms of continence results,
complications and quality of life after a median follow-up of 48 months. Int Urol
Nephrol. 2010 Dec;42(4):915-20

11: Börgermann C, Loertzer H, Luboldt HJ, Hammerer P, Fornara P, Graefen M,
Rübben H. [PSA--Quo vadis?]. Urologe A. 2009 Sep;48(9):1008, 1010, 1012-4,

12: Jeron A, Pfoertner S, Bruder D, Geffers R, Hammerer P, Hofmann R, Buer J,
Schrader AJ. Frequency and gene expression profile of regulatory T cells in renal
cell carcinoma. Tumour Biol. 2009;30(3):160-70.

13: Montorsi F, Alcaraz A, Desgrandchamps F, Hammerer P, Schröder F, Castro R. A
broader role for 5ARIs in prostate disease? Existing evidence and emerging
benefits. Prostate. 2009 Jun 1;69(8):895-907

14: Alcaraz A, Hammerer P, Tubaro A, Schröder FH, Castro R. Is there evidence of
a relationship between benign prostatic hyperplasia and prostate cancer? Findings
of a literature review. Eur Urol. 2009 Apr;55(4):864-73.

15: Boccon-Gibod L, Hammerer P, Madersbacher S, Mottet N, Prayer-Galetti T, Tunn
U. The role of intermittent androgen deprivation in prostate cancer. BJU Int.
2007 Oct;100(4):738-43.

16: Djavan B, Ravery V, Rocco B, Zlotta A, Brausi M, Margreiter M, Hammerer P,
Kaisary A, Anagnostou T, Romics I, Dobronski P, De Cobelli O, Marberger M.
European Study of Radical Prostatectomy: time trends in Europe, 1993-2005. BJU
Int. 2007 Jul;100 Suppl 2:22-5.

17: Börgermann C, Sieverding M, Fornara P, Graefen M, Hammerer P, Semjonow A,
Schröder F, Rübben H. [PSA 2010--the beginning of a new era in early detection of
prostate cancer]. Urologe A. 2006 Sep;45 Suppl 4:127-33.

18: Tilki D, Irmak S, Oliveira-Ferrer L, Hauschild J, Miethe K, Atakaya H,
Hammerer P, Friedrich MG, Schuch G, Galalae R, Stief CG, Kilic E, Huland H, Ergun
S. CEA-related cell adhesion molecule-1 is involved in angiogenic switch in
prostate cancer. Oncogene. 2006 Aug 17;25(36):4965-74.

19: Mottet N, Prayer-Galetti T, Hammerer P, Kattan MW, Tunn U. Optimizing
outcomes and quality of life in the hormonal treatment of prostate cancer. BJU
Int. 2006 Jul;98(1):20-7.

20: Hammerer PG, Kattan MW, Mottet N, Prayer-Galetti T. Using prostate-specific
antigen screening and nomograms to assess risk and predict outcomes in the
management of prostate cancer. BJU Int. 2006 Jul;98(1):11-9.